Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcoma

Pediatric patients with relapsed or refractory rhabdomyosarcoma (RMS) have dismal cure rates, and effective therapy is urgently needed. The oncogenic receptor tyrosine kinase fibroblast growth factor receptor 4 (FGFR4) is highly expressed in RMS and lowly expressed in healthy tissues. Here, we descr...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Meijie, Wei, Jun S., Shivaprasad, Nityashree, Highfill, Steven L., Gryder, Berkley E., Milewski, David, Brown, G. Tom, Moses, Larry, Song, Hannah, Wu, Jerry T., Azorsa, Peter, Kumar, Jeetendra, Schneider, Dina, Chou, Hsien-Chao, Song, Young K., Rahmy, Abdelrahman, Masih, Katherine E., Kim, Yong Yean, Belyea, Brian, Linardic, Corinne M., Dropulic, Boro, Sullivan, Peter M., Sorensen, Poul H., Dimitrov, Dimiter S., Maris, John M., Mackall, Crystal L., Orentas, Rimas J., Cheuk, Adam T., Khan, Javed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10591056/
https://www.ncbi.nlm.nih.gov/pubmed/37774704
http://dx.doi.org/10.1016/j.xcrm.2023.101212

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10591056/
https://www.ncbi.nlm.nih.gov/pubmed/37774704
http://dx.doi.org/10.1016/j.xcrm.2023.101212

Ejemplares similares